|LETTER TO EDITOR
|Year : 2019 | Volume
| Issue : 1 | Page : 53
Justin D Pennington, R Joel Welch, Sara E Lally, Jerry A Shields, Ralph C Eagle Jr , Carol L Shields
Ocular Oncology Service and Department of Pathology, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA
|Date of Web Publication||24-Apr-2019|
Dr. Carol L Shields
Ocular Oncology Service, 840 Walnut Street, Suite 1440, Philadelphia, PA
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Pennington JD, Welch R J, Lally SE, Shields JA, Eagle RC, Shields CL. Authors' Reply. Middle East Afr J Ophthalmol 2019;26:53
|How to cite this URL:|
Pennington JD, Welch R J, Lally SE, Shields JA, Eagle RC, Shields CL. Authors' Reply. Middle East Afr J Ophthalmol [serial online] 2019 [cited 2019 May 21];26:53. Available from: http://www.meajo.org/text.asp?2019/26/1/53/256989
We thank the author for the insightful comments on the potential relationship of HIV with rhabdomyosarcoma. In our case, prior to commencing chemotherapy, the patient's immune status was carefully examined and our patient was HIV negative. We agree that the overlap between cancer and the immune system is fertile ground for our understanding of the pathogenesis, progression, and possible cure of cancer. [1,2]
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy: Systemic indications and ophthalmic side effects. Retina 2018;38:1063-78.
Shields CL, Chien JL, Surakiatchanukul T, Sioufi K, Lally SE, Shields JA, et al.
Conjunctival tumors: Review of clinical features, risks, biomarkers, and outcomes - The 2017 J. Donald M. Gass Lecture. Asia Pac J Ophthalmol (Phila) 2017;6:109-20.